Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)

J. B. Vermorken, W. J. van der Vijgh, I. Klein, H. E. Gall, T. A W Splinter, A. A M Hart, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Total platinum kinetics were studied after the administration of two formulation products of cisplatin: the lyophilized form and a ready-to-use solution. Twelve patients received both preparations during two successive cycles in a randomized crossover study. Platinum concentrations in plasma and urine were measured by atomic absorption spectrometry. Data were analyzed by means of a mixed-effect analysis of variance. Areas under the concentration-time curves up to 96 h were increased (p = 0.026) and slopes of the elimination phase were decreased (p = 0.035) during cycle 2 when compared with cycle 1. However, no difference in these two parameters was observed when comparing the two formulations. Three-day urinary platinum excretion was not related to either the treatment cycle or the formulation used. Because of its convenience of use and reduced risk of aerosolization, the ready-to-use formulation seems preferable.

Original languageEnglish (US)
Pages (from-to)264-268
Number of pages5
JournalTherapeutic Drug Monitoring
Volume8
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Pharmacokinetics
Platinum
Cisplatin
Atomic absorption spectrometry
Analysis of variance (ANOVA)
Cross-Over Studies
Spectrum Analysis
Analysis of Variance
Urine
Plasmas
Kinetics
Therapeutics

Keywords

  • Cisplatin
  • Ready-to-use solution
  • Total platinum pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Public Health, Environmental and Occupational Health

Cite this

Vermorken, J. B., van der Vijgh, W. J., Klein, I., Gall, H. E., Splinter, T. A. W., Hart, A. A. M., & Pinedo, H. M. (1986). Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol). Therapeutic Drug Monitoring, 8(3), 264-268.

Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol). / Vermorken, J. B.; van der Vijgh, W. J.; Klein, I.; Gall, H. E.; Splinter, T. A W; Hart, A. A M; Pinedo, H. M.

In: Therapeutic Drug Monitoring, Vol. 8, No. 3, 1986, p. 264-268.

Research output: Contribution to journalArticle

Vermorken, JB, van der Vijgh, WJ, Klein, I, Gall, HE, Splinter, TAW, Hart, AAM & Pinedo, HM 1986, 'Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)', Therapeutic Drug Monitoring, vol. 8, no. 3, pp. 264-268.
Vermorken JB, van der Vijgh WJ, Klein I, Gall HE, Splinter TAW, Hart AAM et al. Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol). Therapeutic Drug Monitoring. 1986;8(3):264-268.
Vermorken, J. B. ; van der Vijgh, W. J. ; Klein, I. ; Gall, H. E. ; Splinter, T. A W ; Hart, A. A M ; Pinedo, H. M. / Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol). In: Therapeutic Drug Monitoring. 1986 ; Vol. 8, No. 3. pp. 264-268.
@article{f5aa049b727d41f2bdabfaecbab85908,
title = "Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)",
abstract = "Total platinum kinetics were studied after the administration of two formulation products of cisplatin: the lyophilized form and a ready-to-use solution. Twelve patients received both preparations during two successive cycles in a randomized crossover study. Platinum concentrations in plasma and urine were measured by atomic absorption spectrometry. Data were analyzed by means of a mixed-effect analysis of variance. Areas under the concentration-time curves up to 96 h were increased (p = 0.026) and slopes of the elimination phase were decreased (p = 0.035) during cycle 2 when compared with cycle 1. However, no difference in these two parameters was observed when comparing the two formulations. Three-day urinary platinum excretion was not related to either the treatment cycle or the formulation used. Because of its convenience of use and reduced risk of aerosolization, the ready-to-use formulation seems preferable.",
keywords = "Cisplatin, Ready-to-use solution, Total platinum pharmacokinetics",
author = "Vermorken, {J. B.} and {van der Vijgh}, {W. J.} and I. Klein and Gall, {H. E.} and Splinter, {T. A W} and Hart, {A. A M} and Pinedo, {H. M.}",
year = "1986",
language = "English (US)",
volume = "8",
pages = "264--268",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic comparison of cisplatin in solution with common lyophilized cisplatinum (Platinol)

AU - Vermorken, J. B.

AU - van der Vijgh, W. J.

AU - Klein, I.

AU - Gall, H. E.

AU - Splinter, T. A W

AU - Hart, A. A M

AU - Pinedo, H. M.

PY - 1986

Y1 - 1986

N2 - Total platinum kinetics were studied after the administration of two formulation products of cisplatin: the lyophilized form and a ready-to-use solution. Twelve patients received both preparations during two successive cycles in a randomized crossover study. Platinum concentrations in plasma and urine were measured by atomic absorption spectrometry. Data were analyzed by means of a mixed-effect analysis of variance. Areas under the concentration-time curves up to 96 h were increased (p = 0.026) and slopes of the elimination phase were decreased (p = 0.035) during cycle 2 when compared with cycle 1. However, no difference in these two parameters was observed when comparing the two formulations. Three-day urinary platinum excretion was not related to either the treatment cycle or the formulation used. Because of its convenience of use and reduced risk of aerosolization, the ready-to-use formulation seems preferable.

AB - Total platinum kinetics were studied after the administration of two formulation products of cisplatin: the lyophilized form and a ready-to-use solution. Twelve patients received both preparations during two successive cycles in a randomized crossover study. Platinum concentrations in plasma and urine were measured by atomic absorption spectrometry. Data were analyzed by means of a mixed-effect analysis of variance. Areas under the concentration-time curves up to 96 h were increased (p = 0.026) and slopes of the elimination phase were decreased (p = 0.035) during cycle 2 when compared with cycle 1. However, no difference in these two parameters was observed when comparing the two formulations. Three-day urinary platinum excretion was not related to either the treatment cycle or the formulation used. Because of its convenience of use and reduced risk of aerosolization, the ready-to-use formulation seems preferable.

KW - Cisplatin

KW - Ready-to-use solution

KW - Total platinum pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0022496743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022496743&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 264

EP - 268

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -